AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23721547 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (20 or 40 mg once daily, 20 or 30 mg twice daily)
Number of subjects: 460
Study 23721547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 23721547 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbaclofen placarbil (all doses)
Number of subjects: 460
Study 21495899 — intervention group
Group type: EXPERIMENTAL
Intervention: Omelette lunch
Number of subjects: 31
Study 21495899 — intervention group
Group type: COMPARATOR
Intervention: Jacket potato lunch
Number of subjects: 31
Study 21495899 — intervention group
Group type: COMPARATOR
Intervention: Chicken sandwich lunch
Number of subjects: 31
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.00 mmol/L
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.50 mmol/L
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate calcium concentration (D(Ca)) of 1.25 mmol/L
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher D(Ca) levels
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HD
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing level of iCa
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: DeltaMBP
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher DeltaMBP and higher ultrafiltration
Number of subjects: 18
Study 19654232 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation in heart rate and DeltaMBP
Number of subjects: 18
Study 15677600 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (12-16 mg)
Number of subjects: 162
Study 15677600 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (65-85 mg p.o.)
Number of subjects: 162
Study 15677600 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management
Number of subjects: 162
Study 15677600 — intervention group
Group type: COMPARATOR
Intervention: Performance feedback
Number of subjects: 162
Study 12687829 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) catheter ablation of AF
Number of subjects: 69
Study 10592952 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrup of ipecac (SI) + home observation (HO)
Number of subjects: 103
Study 10592952 — intervention group
Group type: COMPARATOR
Intervention: Home observation (HO) alone
Number of subjects: 103
Study 8725983 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics for respiratory tract infections
Number of subjects: 3610
Study 1807700 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized feedback from a clinical preceptor and study librarian on first 10 searches after a 1-hour training class and 1 hour of individualized searching.
Number of subjects: 308
Study 1807700 — intervention group
Group type: COMPARATOR
Intervention: No further intervention after the initial training class.
Number of subjects: 308
Study 6131488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 6131488 — intervention group
Group type: EXPERIMENTAL
Intervention: Halazepam or Oxazepam
Number of subjects: 29
Study 31764271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash transfers
Number of subjects: 0
Study 31764271 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 31764271 — intervention group
Group type: COMPARATOR
Intervention: Food assistance
Number of subjects: 0
Study 31764271 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimized cash transfer intervention
Number of subjects: 0
Study 27770561 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 4 weeks
Number of subjects: 31
Study 27770561 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 6 weeks
Number of subjects: 31
Study 27770561 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 8 weeks
Number of subjects: 31
Study 27770561 — intervention group
Group type: EXPERIMENTAL
Intervention: elbasvir (EBR) 50 mg/grazoprevir (GZR) 100 mg with sofosbuvir (SOF) 400 mg for 12 weeks
Number of subjects: 31
Study 27770561 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with EBR/GZR+SOF and ribavirin for 12 weeks
Number of subjects: 31
Study 27376706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 16 weeks
Number of subjects: 0
Study 27376706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,000 mg/day for 24 weeks
Number of subjects: 0
Study 27376706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 16 weeks
Number of subjects: 0
Study 27376706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg once daily plus ribavirin 1,200 mg/day for 24 weeks
Number of subjects: 0
Study 27376706 — intervention group
Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (both dosages)
Number of subjects: 0
Study 24210653 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cap (cap-assisted gastroscope)
Number of subjects: 139
Study 24210653 — intervention group
Group type: COMPARATOR
Intervention: C-cap (cap-assisted colonoscope)
Number of subjects: 139
Study 22364892 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (botulinum toxin injection to the glabellar region)
Number of subjects: 30
Study 22364892 — intervention group
Group type: COMPARATOR
Intervention: placebo (saline injection)
Number of subjects: 30
Study 22364892 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 30
Study 19581770 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine therapy
Number of subjects: 271
Study 17975845 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD) + standard medical therapy (SMT)
Number of subjects: 70
Study 17975845 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone
Number of subjects: 70
Study 16358599 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine
Number of subjects: 43
Study 16358599 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 43
Study 16358599 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 43
Study 16358599 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 43
Study 16358599 — intervention group
Group type: COMPARATOR
Intervention: No topical anesthetic
Number of subjects: 43
Study 12473473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal mupirocin ointment for 5 days
Number of subjects: 484
Study 12473473 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment with mupirocin
Number of subjects: 484
Study 10496153 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil suspension (10mg/kg/day)
Number of subjects: 57
Study 10496153 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor suspension (45mg/kg/day)
Number of subjects: 57
Study 7650209 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of human herpesvirus 6 (HHV‐6) variant A
Number of subjects: 0
Study 7650209 — intervention group
Group type: COMPARATOR
Intervention: Presence of human herpesvirus 7 (HHV‐7)
Number of subjects: 0
Study 2696009 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (4 mg before or after the operation or 8 mg after the operation)
Number of subjects: 100
Study 2696009 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (16 mg at the end of the operation)
Number of subjects: 100
Study 2696009 — intervention group
Group type: COMPARATOR
Intervention: Nothing (control group)
Number of subjects: 100
Study 326596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol therapy
Number of subjects: 245
Study 326596 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol plus behavioural modification
Number of subjects: 245
Study 326596 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 245
Study 29654540 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week mindfulness intervention
Number of subjects: 145
Study 28885054 — intervention group
Group type: EXPERIMENTAL
Intervention: Zephyr endobronchial valve (EBV) treatment
Number of subjects: 97
Study 28885054 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC)
Number of subjects: 97
Study 25204361 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical minoxidil foam 5% (MTF)
Number of subjects: 16
Study 25204361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 23144466 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (LiveWell, 25 mg three times a day)
Number of subjects: 22
Study 23144466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 21700161 — intervention group
Group type: EXPERIMENTAL
Intervention: Stainless steel piercings
Number of subjects: 85
Study 21700161 — intervention group
Group type: COMPARATOR
Intervention: Polytetrafluoroethylene piercings
Number of subjects: 85
Study 21700161 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene piercings
Number of subjects: 85
Study 21700161 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 85
Study 19394002 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (according to traditional Chinese medicine principles)
Number of subjects: 57
Study 19394002 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 57
Study 17062435 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose omega-3 (4.55 g omega-3/day)
Number of subjects: 24
Study 17062435 — intervention group
Group type: COMPARATOR
Intervention: Low-dose omega-3 (1.95 g omega-3/day)
Number of subjects: 24
Study 14550444 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-gauge coaxial TruGuide needle
Number of subjects: 102
Study 14550444 — intervention group
Group type: COMPARATOR
Intervention: Conventional transperineal technique
Number of subjects: 102
Study 10965421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol hydrochloride injection (Limadol), 100 mg
Number of subjects: 12
Study 10965421 — intervention group
Group type: COMPARATOR
Intervention: Commercially available reference product, 100 mg
Number of subjects: 12
Study 8779143 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Salamol
Number of subjects: 10
Study 8779143 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Salbulin
Number of subjects: 10
Study 8779143 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (1200 micrograms) - Ventolin
Number of subjects: 10
Study 8779143 — intervention group
Group type: COMPARATOR
Intervention: Salbulin vs Ventolin
Number of subjects: 10
Study 8779143 — intervention group
Group type: COMPARATOR
Intervention: Salamol vs Ventolin
Number of subjects: 10
Study 1352908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (800 mg single oral dose)
Number of subjects: 12
Study 1352908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine (3 days treatment)
Number of subjects: 12
Study 1352908 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 days treatment)
Number of subjects: 12
Study 6241188 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.05 mg/kg)
Number of subjects: 191
Study 6241188 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.1 mg/kg)
Number of subjects: 191
Study 6241188 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (0.2 mg/kg)
Number of subjects: 191
Study 6241188 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-cis-retinoic acid (all doses)
Number of subjects: 191
Study 30874474 — intervention group
Group type: EXPERIMENTAL
Intervention: injectable sponge
Number of subjects: 360
Study 30874474 — intervention group
Group type: COMPARATOR
Intervention: plain gauze
Number of subjects: 360
Study 30874474 — intervention group
Group type: EXPERIMENTAL
Intervention: z‐folded gauze
Number of subjects: 360
Study 30874474 — intervention group
Group type: EXPERIMENTAL
Intervention: s‐rolled gauze
Number of subjects: 360
Study 30874474 — intervention group
Group type: EXPERIMENTAL
Intervention: all arms
Number of subjects: 360
Study 29202566 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray-Sol group (18 patients) with HA nebulized using a new nasal device named Spray-Sol
Number of subjects: 33
Study 29202566 — intervention group
Group type: COMPARATOR
Intervention: Spray group (15 patients) with HA nebulized with a common spray
Number of subjects: 33
Study 29202566 — intervention group
Group type: EXPERIMENTAL
Intervention: Spray-Sol group (18 patients)
Number of subjects: 33
Study 29202566 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 25914337 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical onabotulinumtoxinA (BoNT‐A) 100 U
Number of subjects: 60
Study 25914337 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (N/S)
Number of subjects: 60
Study 25027139 — intervention group
Group type: EXPERIMENTAL
Intervention: Telecare management (n=124) for 12 months with automated symptom monitoring and algorithm-guided stepped care approach to optimizing analgesics
Number of subjects: 250
Study 25027139 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=126)
Number of subjects: 250
Study 22470117 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) resistance without rifampin resistance
Number of subjects: 186
Study 22470117 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug resistance
Number of subjects: 186
Study 22470117 — intervention group
Group type: EXPERIMENTAL
Intervention: INH-resistant cases during the continuation phase of treatment (after 3 months)
Number of subjects: 186
Study 22470117 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-susceptible cases infected with 'modern' Beijing lineage strains
Number of subjects: 186
Study 19264840 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein-high red meat (HP) diet
Number of subjects: 33
Study 19264840 — intervention group
Group type: COMPARATOR
Intervention: High carbohydrate (HC) diet
Number of subjects: 33
Study 17135217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 52
Study 17135217 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine plus methylprednisolone
Number of subjects: 52
Study 17135217 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 52
Study 15083919 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 20
Study 15083919 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 20
Study 15083919 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 11991558 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 88 microg twice daily
Number of subjects: 243
Study 11991558 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral zafirlukast (Z) 20 mg twice daily
Number of subjects: 243
Study 11991558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-assist control (56% usage)
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation (SIMV) or SIMV with pressure support
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-control ventilation
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (mean +/- SD)
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau pressures (Pplats)
Number of subjects: 74
Study 11713144 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 74
Study 9203448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine
Number of subjects: 32
Study 9203448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 8135107 — intervention group
Group type: EXPERIMENTAL
Intervention: Dantrolene sodium
Number of subjects: 36
Study 8135107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lioresal
Number of subjects: 36
Study 8135107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3615688 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine (mean dose = 233 mg/day)
Number of subjects: 37
Study 3615688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 29369537 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer 16.8 g/day (divided into two doses) with individualized titration
Number of subjects: 63
Study 27353358 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent graft
Number of subjects: 293
Study 27353358 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 293
Study 24279685 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with mycophenolate and CNI withdrawal (CNI-WD)
Number of subjects: 126
Study 24279685 — intervention group
Group type: COMPARATOR
Intervention: Control (Cyclosporin, mycophenolate and steroids)
Number of subjects: 126
Study 24373555 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed tocotrienols 200 mg twice daily
Number of subjects: 87
Study 24373555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 20360491 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection subcutaneous digital nerve block (SDNB)
Number of subjects: 76
Study 20360491 — intervention group
Group type: COMPARATOR
Intervention: Traditional (two injection) digital nerve block (TDNB)
Number of subjects: 76
Study 18822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specific counselling about 'unrestricted motility' during maternity stay
Number of subjects: 0
Study 18822255 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 18822255 — intervention group
Group type: EXPERIMENTAL
Intervention: Early specific counselling about 'unrestricted motility'
Number of subjects: 0
Study 16491747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10), once each week, for 4 times
Number of subjects: 222
Study 16491747 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at Sifeng (EX‐UE 10)
Number of subjects: 222
Study 16491747 — intervention group
Group type: COMPARATOR
Intervention: Medicine group (Yiqi Jianpi Oral Liquid, twice each day, for 4 weeks)
Number of subjects: 222
Study 16491747 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 222
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic timolol products
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Betimol, Optipranolol, Timoptic
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic timolol XE gel-forming solution
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Betagan, Betoptic S, Ocupress
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Betoptic S
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopidine
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocupress
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilopine gel
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Azopt
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Trusopt
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cosopt (timolol 0.5% plus dorzolamide 2%)
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.15% with Purite (Alphagan-P)
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumigan
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Xalatan
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Travatan
Number of subjects: 0
Study 12834665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescula
Number of subjects: 0
Study 10799190 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin chloride
Number of subjects: 36
Study 10799190 — intervention group
Group type: COMPARATOR
Intervention: Simple saline (control group)
Number of subjects: 36
Study 9008994 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic surgery
Number of subjects: 20
Study 9008994 — intervention group
Group type: EXPERIMENTAL
Intervention: Midlaser therapy with TMJ/occlusal stabilization
Number of subjects: 20
Study 9008994 — intervention group
Group type: COMPARATOR
Intervention: Conservative management alone
Number of subjects: 20
Study 1503285 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (Group B)
Number of subjects: 14
Study 1503285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine combined with fentanyl (Group B+F)
Number of subjects: 14
Study 28592888 — intervention group
Group type: EXPERIMENTAL
Intervention: GRAALL treatment
Number of subjects: 127
Study 29106437 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 units of abobotulinumtoxinA injected in 5 equal aliquots (24 units each) into 5 injection sites in the glabellar complex
Number of subjects: 30
Study 29106437 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 units of abobotulinumtoxinA
Number of subjects: 30
Study 24359563 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention (WBI; Avanti)
Number of subjects: 67
Study 24359563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 67
Study 22472580 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention over 12 months
Number of subjects: 149